Statin adverse events in primary prevention: Between randomized trials and observational studies

American Journal of the Medical Sciences

Volumn 350, Issue 4, 2015, Pages 330-337

  Mansi, Ishak ^a   Palmer, Biff F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adverse events; Observational studies; Primary prevention; Randomized trials; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADVERSE DRUG REACTION; ARTICLE; ASCERTAINMENT BIAS; CLINICAL ASSESSMENT; CLINICAL RESEARCH; CONFLICT OF INTEREST; DRUG ACTIVITY; DRUG EFFECT; FUNDING; HEART PROTECTION; HUMAN; INTENTION TO TREAT ANALYSIS; MEDICAL TECHNOLOGY; META ANALYSIS (TOPIC); OBSERVATIONAL STUDY; PLEIOTROPIC ACTIVITY; PRIMARY PREVENTION; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STATISTICAL ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC); TREATMENT REFUSAL; CARDIOLOGY; CARDIOVASCULAR DISEASES; METHODOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PROCEDURES; UNITED STATES;

CARDIOLOGY; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OBSERVATIONAL STUDIES AS TOPIC; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; PRIMARY PREVENTION; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; UNITED STATES;

EID: 84942789057     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000527     Document Type: Article

References (99)

1. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
2. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005;46:1855-62.
3. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New Engl Journal Medicine 2004;350:1495-504.
4. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New Engl J Med 2005;352:1425-35.
5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of Cardiology/American heart association task force on practice guidelines. Circulation 2014;129:S1-S45.
6. Kolata G Risk calculator for cholesterol appears flawed. The New York Times. November 18, 2013 ed. New York; 2013. p. A1.
7. Kavousi M, Leening MJ, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014;311:1416-23.
8. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med 2000;343:475-80.
9. Blauwet LA, Redberg RF. The role of sex-specific results reporting in cardiovascular disease. Cardiol Rev 2007;15:275-8.
10. Ma Y, Culver A, Rossouw J, et al. Statin therapy and the risk for diabetes among adult women: do the benefits outweigh the risk? Ther Advances Cardiovascular Disease 2013;7:41-4.
11. Thavendiranathan P, Bagai A, Brookhart MA, et al. Primary prevention of cardiovascular diseases with statin therapy: A metaanalysis of randomized controlled trials. Arch Intern Med 2006; 166:2307-13.
12. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816.
13. Cochrane review stirs controversy over statins in primary prevention. Medscape; Jan 21, 2011; available at: http://www.medscape.com/viewarticle/736131.
14. Han BH, Weinberger Y, Sutin D. Statinopause. J General Internal Medicine 2014;29:1702-6.
15. Finegold JA, Manisty CH, Goldacre B, et al. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebocontrolled trials to aid individual patient choice. Eur J Prev Cardiol 2014;21:464-74.
16. Gutierrez J, Ramirez G, Rundek T, et al. Statin therapy in the prevention of recurrent cardiovascular events: A sex-based meta-analysis. Arch Intern Med 2012;172:909-19.
17. Cholesterol Treatment Trialists Collaborators. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174, 000 participants in 27 randomised trials. Lancet 2015;385:1397-405.
18. Mansi I, Mortensen E. The controversy of a wider statin utilization: Why? Expert Opin Drug Saf 2013;12:327-37.
19. Martini C, Pallottini V. Cholesterol: from feeding to gene regulation. Genes Nutr 2007;2:181-93.
20. Goedeke L, Fernandez-Hernando C. Regulation of cholesterol homeostasis. Cell Mol Life Sci 2012;69:915-30.
21. Zhou Q, Liao JK. Pleiotropic effects of statins-Basic research clinical perspectives. Circ J 2010;74:818-26.
22. Chow SC. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp (warsz) 2009;57:243-51.
23. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31.
24. Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011;215:1-8.
25. Matsumoto M, Einhaus D, Gold ES, et al. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J Immunol 2004;172:7377-84.
26. De-Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333-7.
27. Golomb BA, Evans MA. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8:373-418.
28. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials. Lancet 2015;385:351-61.
29. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006;97:69C-76C.
30. Fernandez G, Spatz ES, Jablecki C, et al. Statin myopathy: A common dilemma not reflected in clinical trials. Cleveland Clin J Med 2011;78: 393-403.
31. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients- The PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14.
32. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
33. Marie I, Delafenetre H, Massy N, et al. Tendinous disorders attributed to statins: A study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum 2008;59: 367-72.
34. Carmont MR, Highland AM, Blundell CM, et al. Simultaneous bilateral Achilles tendon ruptures associated with statin medication despite regular rock climbing exercise. Phys Ther Sport 2009;10:150-2.
35. Beri A, Dwamena FC, Dwamena BA. Association between statin therapy and tendon rupture: A case-control study. J Cardiovascu Pharmacol 2009;53:401-4.
36. Pullatt RC, Gadarla MR, Karas RH, et al. Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol 2007;100:152-3.
37. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90.
38. Draeger A, Monastyrskaya K, Mohaupt M, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94-102.
39. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581-5.
40. Yang KC, Chien JY, Tseng WK, et al. Statins do not improve shortterm survival in an oriental population with sepsis. Am J Emerg Med 2007;25:494-501.
41. Wagstaff LR, Mitton MW, Arvik BM, et al. Statin-associated Memory Loss: Analysis 60 Case Reports Review Literature. Pharmacotheraphy 2003;23:871-80.
42. Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009;29:800-11.
43. Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004;117:823-9.
44. Mansi I, Frei CR, Pugh MJ, et al. Psychologic disorders and statin use: A propensity score-matched analysis. Pharmacotherapy 2013;33:615-26.
45. Lilly SM, Mortensen EM, Frei CR, et al. Comparison of the risk of psychological and cognitive disorders between persistent and nonpersistent statin users. Am J Cardiol 2014;114:1035-9.
46. FDA Drug Saftey Communication. Important safety label changes to cholesterol-lowering statin drugs. The U S Food and Drug Administration; 2012. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed July 6, 2015.
47. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197.
48. Mason RP, Walter MF, Day CA, et al. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 2005; 96:11F-23F.
49. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-8.
50. Yamazaki M, Akiyama S, Ni'inuma K, et al. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos 1997;25:1123-9.
51. Vgontzas AN, Kales A, Bixler EO, et al. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991;50:730-7.
52. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003;361: 2005-16.
53. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
54. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30.
55. Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001;322:11-5.
56. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
57. Coordinators for the, Allhat Collaborative Research Group The Antihypertensive Lipid-Lowering Treatment to Prevent Heart Attack, Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. Dec 18 2002;288(23):2998-3007.
58. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58.
59. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85.
60. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
61. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006;368:1155-63.
62. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
63. Stewart LA, Parmar MK. Bias in the analysis and reporting of randomized controlled trials. Int J Technol Assess Health Care 1996;12: 264-75.
64. Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: A meta-analysis. Arch Gen Psychiatry 2005;62:1305-12.
65. Rothman KJ. Six persistent research misconceptions. J General Internal Medicine 2014;29:1060-4.
66. Launer LJ, Wind AW, Deeg DJ. Nonresponse pattern and bias in a community-based cross-sectional study of cognitive functioning among the elderly. Am J Epidemiol 1994;139:803-12.
67. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 2012;157:263-75.
68. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011:CD004816.
69. Psaty BM, Furberg CD, Ray WA, et al. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. JAMA 2004;292:2622-31.
70. Jacobson TA. Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc 2008;83:687-700.
71. Hsia J, MacFadyen JG, Monyak J, et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol, 50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011;57:1666-75.
72. Buettner C, Davis RB, Leveille SG, et al. Prevalence of musculoskeletal pain and statin use. J General Intern Med 2008;23:1182-6.
73. Buettner C, Rippberger MJ, Smith JK, et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012; 125:176-82.
74. Hoffman R, Lim H. Observational study design. In: Ambrosius W, editor. Topics in biostatistics. New Jersey, NJ: Humana Press; 2007. p. 19-30.
75. Hemmila MR, Birkmeyer NJ, Arbabi S, et al. Introduction to propensity scores: A case study on the comparative effectiveness of laparoscopic vs open appendectomy. Arch Surg 2010;145:939-45.
76. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9.
77. Schneeweiss S, Seeger JD, Maclure M, et al. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-64.
78. Perkins AJ, Kroenke K, Unutzer J, et al. Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol 2004;57:1040-8.
79. Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med 2011;184:312-6.
80. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: A comprehensive review. Expert Opin Drug Saf 2010;9:603-21.
81. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: A cautionary tale. Circulation 2009;119:2051-7.
82. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipidlowering therapy and the use of preventive health services: An investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54.
83. McWilliams JM, Zaslavsky AM, Meara E, et al. Impact of medicare coverage on basic clinical services for previously uninsured adults. JAMA 2003;290:757-64.
84. Friedman E. The uninsured. From dilemma to crisis. JAMA 1991;265: 2491-5.
85. McWilliams JM. Health consequences of uninsurance among adults in the United States: Recent evidence and implications. Milbank Q 2009; 87:443-94.
86. Glantz S, Slinker B. Primer of applied regression and analysis of variance. 2nd ed. New York, NY: McGraw-Hill, Inc; 2001.
87. Raphael KG, Cloitre M. Does mood-congruence or causal search govern recall bias? A test of life event recall. J Clin Epidemiol 1994; 47:555-64.
88. Patrick AR, Schneeweiss S, Brookhart MA, et al. The implications of propensity score variable selection strategies in pharmacoepidemiology: An empirical illustration. Pharmacoepidemiol Drug Saf 2011; 20:551-9.
89. Campbell M. Statistics at square two understanding modern statistical applications in medicine. 1st ed. London, England: BMJ; 2001.
90. Toh S, Hernandez-Diaz S. Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 2007;16:627-40.
91. Sugiyama T, Tsugawa Y, Tseng CH, et al. Different time trends of caloric and fat intake between statin users and nonusers among US adults: Gluttony in the time of statins? JAMA Intern Med 2014;174: 1038-45.
92. Lee DS, Markwardt S, Goeres L, et al. Statins and physical activity in older men: The osteoporotic fractures in men study. JAMA internal medicine. Aug 2014;174:1263-70.
93. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-52.
94. Chen CW, Chen TC, Huang KY, et al. Differential impact of statin on new-onset diabetes in different age groups: A population-based case-control study in women from an asian country. PLoS One 2013;8:e71817.
95. Currie O, Mangin D, Williman J, et al. The comparative risk of newonset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: A national cohort study. BMJ Open 2013;3: E003475.
96. Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012;380:565-71.
97. Frayling TM. Statins and type 2 diabetes: genetic studies on target. Lancet 2015;385:310-12.
98. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
99. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A metaanalysis. JAMA 2011;305:2556-64.